BidaskClub upgraded shares of Fortress Biotech (NASDAQ:FBIO) from a sell rating to a hold rating in a research note released on Sunday, March 11th.
Other analysts have also issued reports about the stock. ValuEngine lowered shares of Fortress Biotech from a hold rating to a sell rating in a research report on Friday, December 1st. HC Wainwright set a $11.00 target price on shares of Fortress Biotech and gave the stock a buy rating in a research report on Tuesday, January 2nd. Zacks Investment Research lowered shares of Fortress Biotech from a hold rating to a sell rating in a research report on Monday, February 19th. Finally, B. Riley began coverage on shares of Fortress Biotech in a research report on Wednesday, February 28th. They set a buy rating and a $10.00 target price on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $10.75.
Shares of FBIO stock traded down $0.26 during trading hours on Friday, hitting $4.82. The company’s stock had a trading volume of 93,457 shares, compared to its average volume of 161,302. The firm has a market capitalization of $261.85, a PE ratio of -2.99 and a beta of 0.23. Fortress Biotech has a twelve month low of $3.13 and a twelve month high of $5.54. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.72 and a quick ratio of 2.71.
COPYRIGHT VIOLATION NOTICE: “Fortress Biotech (FBIO) Lifted to “Hold” at BidaskClub” was published by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://baseballnewssource.com/2018/04/06/fortress-biotech-fbio-upgraded-to-hold-at-bidaskclub/2034426.html.
Fortress Biotech Company Profile
Fortress Biotech, Inc develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States.
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.